Ferdy Ferdian
Departement Of Internal Medicine, Faculty Of Medicine Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

Correlation of Serum Anti-Clq Antibody Levels and Disease Activity in Patients with Systemic Lupus Erythematosus Ferdy Ferdian; Riardi Pramudiyo; Laniyati Hamijoyo
Indonesian Journal of Rheumatology Vol. 11 No. 1 (2019): Indonesian Journal of Rheumatology
Publisher : Indonesian Rheumatology Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/ijr.v11i1.116

Abstract

Background. Antibody to complement C1q (Anti-C1q Antibody) can be found in Systemic Lupus Erythematosus (SLE) patients. Complement C1q plays a role in the clearance of apoptotic cells and immune complexes. Anti-C1q causes complement C1q become inactive so that the clearance decreases, which induces self antigen and inflammatory response. Many tissue inflammation are associated with disease activity and lupus manifestations. The aim of this study is to find out the correlation of anti-C1q level with disease activity, so that anti-C1q can be used as an objective indicator of inflammation along with SELENA-SLEDAI. Method. This is an analytic descriptive study with cross sectional design. Anti-C1q antibody levels were measured in 52 SLE patients who are hospitalized or treated routinely in outpatient clinic of Rheumatology Dr.Hasan Sadikin Hospital Bandung Indonesia from October to December 2015. Result. Most of the study subjects were women (94%), with a median age of 33 years. There were 13 new patients (25%), and the rest 42 patients were treated routinely. The median SELENA-SLEDAI was 6 (0-32). Subject were divided into no activity (11.5%), low disease activity (34.6%), medium disease activity (25%) high disease activity (15.4%) and very high disease activity (13.5%). Median anti-C1q level was 3.92 U/mL (range 0.6-100.2 U/mL). Anti-C1q antibody levels were positively correlated with SLE disease activity based on SELENA-SLEDAI scores (r=+0.304; p=0.014) Conclusion. Anti-C1q antibody levels has mild correlated with lupus disease activity based on SELENA-SLEDAI score Keywords : Anti-C1q antibody, SLE, SELENA-SLEDAI.
Differential Diagnosis of Fever of Unknown Origin in Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) Kevin Fachri Muhammad; Ferdy Ferdian; Andri Reza Rahmadi
International Journal of Integrated Health Sciences Vol 10, No 1 (2022)
Publisher : Faculty of Medicine Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15850/ijihs.v10n1.2198

Abstract

Objective: To describe an unusual case of drug reaction with eosinophilia and systemic symptoms presenting as fever of unknown origin (FUO) and the diagnostic hurdles that come with the presence of differential diagnosis of FUO, which is tuberculous lymphadenitis.Methods: A 34-year-old female with a chief complaint of fever that has lasted for 3 weeks accompanied with jaundice and skin rashes for 2 weeks was admitted with an indication of FUO. She had a history of carbamazepine consumption for trigerminal neuralgia 2 months prior. Cervical lymphadenopathy was palpable bilaterally and hepatomegaly, elevated liver enzyme, as well as hyperbilirubinemia were observed. After excluding differentials for many causes of prolonged fever, patient was treated for Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) and was given intravenous steroid injections. Fine needle aspiration biopsy was performed for her cervical lymphadenopathy.Results: Biopsy presented a mix of sialadenitis and tuberculous lymphadenopathy. Clinical improvement was observed on the second day after steroid administration. Patient was discharged on the seventh day after steroid administration.  Conclusion: FUO is one of the possible manifestations of DRESS; however, thorough investigation still needed to be done considering the possibility of more than one entity of disease that can cause FUO in patients, such as tuberculous lymphadenopathy seen in this case.
Distribution of Rifampicin-Resistant Tuberculosis Patients based on Presumptive Drug-Resistant Tuberculosis Criteria at Dr. Hasan Sadikin Hospital 2016–2019 Dinda Nursyafira Misyatin; Arto Yuwono Soeroto; Ferdy Ferdian
Althea Medical Journal Vol 9, No 4 (2022)
Publisher : Faculty of Medicine Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15850/amj.v9n4.2593

Abstract

Background: Diagnosis of drug-resistant tuberculosis (DR-TB) begins with identifying presumptive DR-TB patients using Xpert MTB/RIF, as a diagnostic test to detect resistance to rifampicin. The study aimed to identify the distribution of rifampicin-resistant tuberculosis (RR-TB) patients based on presumptive DR-TB criteria at Dr. Hasan Sadikin General Hospital Bandung. Moreover, this study also explored the Xpert MTB/RIF Ct values.Methods: This was a descriptive-retrospective study from 570 medical records of DR-TB patients collected at the Multidrug-resistant tuberculosis (MDR-TB) clinic of Dr. Hasan Sadikin General Hospital from 2016 to 2019. The inclusion criteria were suspected patients with the Xpert MTB/RIF Ct values in the very low-low and medium-high categories. Data were analyzed using frequency distribution. Results: The most common presumptive DR-TB criteria among DR-TB patients were relapse cases (52.3%). Presumptive DR-TB criteria, with a high percentage result of medium-high Ct values, were category II treatment failure (80.9%).Conclusion: Relapse case and category II treatment failure are presumptive DR-TB criteria, which need more attention from clinicians.
The Combination of Gardenia jasminoides, Boswellia serrata, Commiphora myrrha, Foeniculum vulgarae, and Daucus carota Essential Oil Blend Improved the Inflammatory and Clinical Status in Respiratory Tract Infection of COVID-19 Patients: A Multicentre, Randomized, Open-label, Controlled Trial Keri Lestari; Haig Babikian; Iceu Dimas Kulsum; Ferdy Ferdian; Efriadi Ismail; Yelsen Sumalim; Setiawan Setiawan; Prayudi Santoso; Yovita Hartantri; Arief Riadi Arifin; Anna Meiliana; Ida Paulina Sormin; Erizal Sugiono
The Indonesian Biomedical Journal Vol 16, No 3 (2024)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v16i3.3023

Abstract

BACKGROUND: Essential oils (EO) are complex volatile, naturally synthesized compounds from aromatic plants. It considers as healthy, effective, and safe since they were coming from nature. Gardenia jasminoides, Boswellia serrata, Commiphora myrrha, Foeniculum vulgarae, and Daucus carota are known to have antimicrobials, antioxidants, antiinflammation properties against respiratory tract infection. However, despite its natural content, a safety profile needs to be observed. Therefore, in this study, EO blend (EOB) made from the combination of these 5 plants was assessed for its efficacy and safety for respiratory tract infection in human.METHODS: A multicentre, randomized, open-label, phase II controlled trial involving 80 hospitalized adults with COVID-19 was conducted. One group of subjects only received standard of care (SoC), while the other group receive SoC and EOB orally for 10 days.RESULTS: There were significant decrease in interleukin (IL)-6 level (p=0.016) and interferon (IFN)-γ level (p=0.012), as well as better respiratory rate (p=0.024) for the group receiving SoC and EOB compared to the group receiving SoC only. However, there was no significant differences in aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, and the corrected QT interval (QTc) prolongation value in both groups. All subjects with adverse effects were improved and recovered, and there were no serious adverse events found.CONCLUSION: The combination of G. jasminoides, B. serrata, C. myrrha, F. vulgarae, and D. carota EOB could improve the inflammatory and clinical status and safe to be used as adjuvant therapy for treating COVID-19 in adults.KEYWORDS: essential oils, COVID-19, inflammation, safety